Clinical studies regarding the role of GLP1-R agonists, such as exendin-4, liraglutide and lixisenatide in PD also show improvement in motor and cognitive functions, as well as in the daily living parameters of these patients, reinforcing the ambition to identify novel PD modifying agents. The gene discussed is GLP1R; the disease is Parkinson disease.